Mylan (VRTS) Wins Summary Judgment in EpiPen Litigation Brought by Sanofi (SNY)

Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen® products.

Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi's baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen and goes a long way in supporting the Company's commitment to vigorously defend itself against unfounded claims.

For the past three years, Sanofi, one of the world's largest pharmaceutical companies, has unjustly pursued money damages and attempted to blame Mylan for Sanofi's own failures in marketing Auvi-Q. The Court's favorable judgment should put an end to this attempt by Sanofi to advance a false narrative against Mylan and to use the antitrust laws to punish, rather than promote, competition. More than five years ago, Sanofi completely recalled Auvi-Q from the market and decided to return the product to the inventor after the product was found to potentially have inaccurate dosage delivery.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Lazard Global Total Return fund declares $0.1534 monthly distribution
• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests